Maze Therapeutics (MAZE) Accumulated Expenses (2024 - 2026)

Maze Therapeutics' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 53.07% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (down 53.07% YoY), while the FY2025 annual figure was $16.0 million, up 13.23% from the prior year.
• Accumulated Expenses came in at $5.4 million for Q1 2026 at Maze Therapeutics, down from $16.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.0 million in Q4 2025 to a low of $5.4 million in Q1 2026.
• A 3-year average of $11.2 million and a median of $12.8 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses climbed 13.23% in 2025 and tumbled 53.07% in 2026, its largest moves.
• Maze Therapeutics' Accumulated Expenses stood at $14.1 million in 2024, then advanced by 13.23% to $16.0 million in 2025, then slumped by 66.09% to $5.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.4 million, $16.0 million, and $14.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison